SERVIFY
Servify , a leading provider of Extended Care and Product Protection solutions using its global, AI-enabled, digital platform, has announced hiring of senior leaders across regions and functions to drive its global expansion. Arun Verma, MS Kalsi, Kevin Cundiff, Edward Lee, Swetha Prashant, Peter Duesing, Sanghoon (Sam) Kwon, Hussein Hussein and Sergey Odinets have all been hired to bolster various verticals and regions within the organisation.
Arun Verma, with more than 20 years of experience, was appointed as the Chief Human Resources Officer . He has championed impressive success in people management across distinctly diverse industries such as Technology & Services, Finance, Management Consulting & FMCG. He worked as CHRO and Head of Administration of Beetel before Servify, and with the likes of Xerox India, McKinsey & Co., Reliance Capital Limited, and CavinKare in the past.
Makhan Singh Kalsi, also known as M S Kalsi, joins Servify as its Chief Service Officer after previously serving as the Chief Operations Officer for Digicare, a Quess Group Company. During his three years there, he scaled their operations multi-fold, with his enviable brand relationships and market reputation. He has also worked with LeEco, Samsung, Nokia, Canon, and Network Ltd in the past in various senior management positions.
Swetha Prashant joined Servify as Group General Counsel and shall be working closely with the leadership team to help scale and reinforce Servify’s legal capabilities. Swetha, a former partner of J. Sagar Associates (a leading law firm), has been practising law for more than 14 years with extensive experience in representing and advising both domestic and international clients in relation to cross border investments, M&A, JVs, private equity / venture capital, and general corporate commercial transactions and compliances across diverse sectors.
Kevin Cundiff joins Servify’s North American operations as Vice President, Partners & Account Management, and will manage all key partner relations. He has led teams responsible for product placement as well as client acquisition, development and retention in his previous roles and manage all key account relationships in North America. In the past, he has worked in senior positions at Penumbra Brands, uBreakiFix (acquired by Asurion), Fortegra (ProtectCELL parent company) and T-Mobile.
Edward Lee is an insurance industry veteran with a career spanning more than 20 years spearheaded market expansion, product development and regulatory compliance initiatives in support of global manufacturers, distributors and automotive dealer groups in both Canada and the United States for organisations such as Microsoft Corporation, CNH Industrial N.V., SquareTrade, HomeServe USA, Sears, General Motors Corp., Volvo North America, etc. He joins Servify as Vice President and Head of Insurance for North America and will also drive regulatory compliance in the warranty practice globally for Servify.
Sanghoon (Sam) Kwon joined Servify as a Senior Director and will manage Samsung as an OEM account for Servify. He comes with a rich experience which ranges from strategy building to managing global and regional businesses. He worked with Samsung Electronics in Korea and in other geographies in the past & Bolttech just before joining Servify. He is based in Seoul, South Korea.
The Technology function also sees addition of two key hires.
Dr. Peter Duesing, who became part of Servify after its acquisition of German based WebToGo, takes over the position of Vice President - Technology based out of Munich, Germany. He is now responsible for leading engineering teams for our Diagnostics and R&D functions and will also lead our patent portfolio expansion initiatives.
Ghanshyam Varindani joins Servify as Senior Director to lead the Data Engineering function. In previous roles, he has worked in senior roles at AirAsia in Malaysia and TCS leading Data Analytics Strategy and the Business Intelligence Roadmaps.
Additionally, to manage business operations in The Kingdom of Saudi Arabia & Russia, Hussein Hussein and Sergey Odinets have been respectively appointed as Regional Heads. They both have more than a decade of experience each working for top global brands.
“We are fortunate to build a global business that’s also growing massively. I am extremely proud to have these reputed leaders joining me to realise our vision. It’s always great people building great companies, and I am happy that getting great people hasn’t been a problem ever for us,” said Sreevathsa Prabhakar, Founder of Servify, on the expansion of global teams.
About Servify
Servify integrates multiple OEM Brands and their sales and service ecosystem through its product lifecycle management platform, to deliver great after-sales service experience. Started in 2015, India Headquartered Servify has spread its reach in multiple countries across the globe, partnering with over 75 OEM brands including top mobile device brands, retailers, distributors, insurers, service providers and carriers. The Servify platform processes more than 3 million transactions monthly, with 250k+ Platform users spread across retailers, service centres, contact centres and administration teams worldwide serving millions of consumers.
Additional information on Servify is available at www.servify.tech
View source version on businesswire.com: https://www.businesswire.com/news/home/20210804005106/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
